Capstone Holding shareholders back cut in authorized common shares to as low as 5,000,000

• Capstone Therapeutics’ board adopted resolutions on Aug. 7, 2026 to pursue amendments cutting authorized common and preferred shares.
• Shareholders holding 56.4% of voting power delivered written consent the same day, clearing both actions without a meeting.
• Board gained authority to exchange Series Z 8% Non-Convertible Preferred Stock and accrued management fees for up to 15,750,000 common shares.
• Exchange pricing set at 103% of the Nasdaq Official Closing Price before each transaction; recipients to sign 18-month lock-ups.
• Actions take effect no earlier than 20 days after the information statement is mailed on or about Oct. 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-031618), on September 30, 2026, and is solely responsible for the information contained therein.